CN115919710A - Soothing and anti-allergy composition and preparation method and application thereof - Google Patents
Soothing and anti-allergy composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN115919710A CN115919710A CN202211604730.3A CN202211604730A CN115919710A CN 115919710 A CN115919710 A CN 115919710A CN 202211604730 A CN202211604730 A CN 202211604730A CN 115919710 A CN115919710 A CN 115919710A
- Authority
- CN
- China
- Prior art keywords
- soothing
- allergy
- extract
- allergy composition
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 230000003266 anti-allergic effect Effects 0.000 title claims abstract description 68
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000000284 extract Substances 0.000 claims abstract description 28
- CCOQPGVQAWPUPE-UHFFFAOYSA-N 4-tert-butylcyclohexan-1-ol Chemical compound CC(C)(C)C1CCC(O)CC1 CCOQPGVQAWPUPE-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229940091886 4-tert-butylcyclohexanol Drugs 0.000 claims abstract description 10
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 claims abstract description 9
- 229940044176 ceramide 3 Drugs 0.000 claims abstract description 9
- 230000000694 effects Effects 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 8
- 235000011751 Pogostemon cablin Nutrition 0.000 claims abstract description 7
- 240000002505 Pogostemon cablin Species 0.000 claims abstract description 7
- 229940082906 centella asiatica leaf extract Drugs 0.000 claims abstract description 6
- 239000000419 plant extract Substances 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims abstract description 5
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 4
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000008367 deionised water Substances 0.000 claims description 18
- 229910021641 deionized water Inorganic materials 0.000 claims description 18
- 239000006210 lotion Substances 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 241001529821 Agastache Species 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 241001453830 Pteridium Species 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000003750 conditioning effect Effects 0.000 claims description 2
- 230000001815 facial effect Effects 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 238000009499 grossing Methods 0.000 claims description 2
- 239000003906 humectant Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 230000008591 skin barrier function Effects 0.000 abstract description 13
- 230000008439 repair process Effects 0.000 abstract description 10
- 230000004888 barrier function Effects 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 239000002537 cosmetic Substances 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 230000007774 longterm Effects 0.000 abstract description 6
- 230000035945 sensitivity Effects 0.000 abstract description 6
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 208000003251 Pruritus Diseases 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 4
- 230000007803 itching Effects 0.000 abstract description 4
- 210000005036 nerve Anatomy 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 241000132536 Cirsium Species 0.000 abstract description 3
- 208000027418 Wounds and injury Diseases 0.000 abstract description 3
- 230000001914 calming effect Effects 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 3
- 208000014674 injury Diseases 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 49
- 230000000052 comparative effect Effects 0.000 description 27
- 238000012360 testing method Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 11
- 108010003272 Hyaluronate lyase Proteins 0.000 description 10
- 102000001974 Hyaluronidases Human genes 0.000 description 10
- 229960002773 hyaluronidase Drugs 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 8
- 102100028314 Filaggrin Human genes 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 230000037307 sensitive skin Effects 0.000 description 6
- 210000000434 stratum corneum Anatomy 0.000 description 6
- 238000007599 discharging Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 4
- 239000011449 brick Substances 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 229960005323 phenoxyethanol Drugs 0.000 description 4
- 241000207929 Scutellaria Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000000498 stratum granulosum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000545417 Aleurites Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010015946 Eye irritation Diseases 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 102000005806 Serine Peptidase Inhibitor Kazal-Type 5 Human genes 0.000 description 2
- 108010005020 Serine Peptidase Inhibitor Kazal-Type 5 Proteins 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940059958 centella asiatica extract Drugs 0.000 description 2
- 230000006003 cornification Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 231100000013 eye irritation Toxicity 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 241000199899 Alariaceae Species 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 244000146462 Centella asiatica Species 0.000 description 1
- 235000004032 Centella asiatica Nutrition 0.000 description 1
- 102100038199 Desmoplakin Human genes 0.000 description 1
- 108091000074 Desmoplakin Proteins 0.000 description 1
- 231100000635 Draize test Toxicity 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101710088660 Filaggrin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 101000964562 Homo sapiens Zinc finger FYVE domain-containing protein 9 Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102100033257 Inversin Human genes 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- PJAAESPGJOSQGZ-DZGBDDFRSA-N Isovelleral Chemical compound O=CC1=C[C@@H]2CC(C)(C)C[C@@H]2[C@@]2(C)C[C@]21C=O PJAAESPGJOSQGZ-DZGBDDFRSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 241000737257 Pteris <genus> Species 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229940126422 TRPV1 antagonist Drugs 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040801 Zinc finger FYVE domain-containing protein 9 Human genes 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical group C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- -1 superoxide anions Chemical class 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to a soothing and anti-allergy composition and a preparation method and application thereof, belonging to the technical field of cosmetics. The soothing and anti-allergy composition provided by the invention can achieve the effects of relieving, resisting inflammation and repairing barriers after being compounded by ceramide 3, 4-tert-butylcyclohexanol, a Cirsium plant extract, a patchouli leaf extract, a centella asiatica leaf extract and a scutellaria baicalensis root extract; the relieving and anti-allergy composition provided by the invention can timely eliminate the symptoms such as burning, itching, stabbing pain and tightness caused by inflammation injury and the like after being used for a short time, reduce the nerve sensitivity and play a role in calming and relieving; the long-term use of the skin care product is beneficial to the repair of the skin barrier, and the skin care product has the performance of instant comfort and long-term repair. The invention also provides a preparation method and application of the composition, and the preparation method is simple in process and easy for industrial production.
Description
Technical Field
The invention belongs to the technical field of cosmetics, and particularly relates to a soothing and anti-allergy composition as well as a preparation method and application thereof.
Background
Sensitive skin refers to a high-response state of skin under physiological or pathological conditions, and is characterized by subjective symptoms such as burning, itching, stabbing pain and tightness of skin, and objective signs such as erythema, scales and telangiectasia. More and more people have been afflicted with the problem of sensitive skin in recent years. The research shows that the proportion of the female sensitive skin is 60 to 70 percent, and the proportion of the male sensitive skin is 50 to 60 percent. There are many factors that cause skin sensitivity, such as oxidative stress caused by ultraviolet irradiation, excessive loss of skin lipids caused by improper use of cleansing products, breakdown of skin barrier function, air pollution, stress, etc., and even season changes. Currently, it is widely studied that the development of sensitive muscles is a complex process involving the skin barrier-neurovascular-immune inflammation. Under the interaction of internal and external causes, the barrier function of the skin is damaged, so that sensory nerve afferent signals are increased, the reactivity of the skin to external stimuli is enhanced, and skin immune inflammatory response is initiated.
According to the classification rules and the classification catalogues of cosmetics, the relieving efficacy is one of the cosmetic efficacies, and the explanation and explanation of the relieving efficacy are as follows: soothing refers to helping to improve the state of skin irritation, etc. Data published in 2021 mei yi science and technology white paper show that more than 50% of consumers have needs for skin color brightening, moisture retention, fine line improvement, soothing and the like in the functional cosmetics purchased by the consumers. The relief is ranked fourth and is one of the greatest effects demanded by consumers.
The solution to the skin sensitivity problem can be addressed from two main aspects, namely, repairing the skin barrier, and soothing the inflammatory response of the skin. Most products for sensitive skin on the market today are designed to relieve the inflammatory response of the skin or to repair the skin barrier as a function of the product. The effect is not ideal because the comprehensive consideration is less based on two aspects.
Disclosure of Invention
The invention relates to a soothing and anti-allergy composition and a preparation method and application thereof, belonging to the technical field of cosmetics. The soothing and anti-allergy composition provided by the invention can achieve the effects of relieving, resisting inflammation and repairing barriers after being compounded by ceramide 3, 4-tert-butylcyclohexanol, a Cirsium plant extract, a patchouli leaf extract, a centella asiatica leaf extract and a scutellaria baicalensis root extract; the relieving and anti-allergy composition provided by the invention can timely eliminate the symptoms such as burning, itching, stabbing pain and tightness caused by inflammation injury and the like after being used for a short time, reduce the nerve sensitivity and play a role in calming and relieving; the long-term use of the skin care product is beneficial to the repair of the skin barrier, and the skin care product has the performance of instant comfort and long-term repair. The invention also provides a preparation method and application of the composition, and the preparation method is simple in process and easy for industrial production.
The purpose of the invention can be realized by the following technical scheme:
a soothing and anti-allergy composition comprises the following raw materials in percentage by mass:
in a preferred embodiment of the present invention, the ceramide 3 may be 0.1 to 0.5% by mass, for example, 0.1%, 0.2%, 0.3%, 0.4% or 0.5%.
Ceramide 3 can reestablish the adhesiveness of cells, maintain the skin's moisture saturation, repair dry and damaged skin quickly, and help the renewal of the skin's natural protective layer.
In a preferred embodiment of the present invention, the 4-t-butylcyclohexanol to be added is 0.4 to 1% by mass, for example, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9% or 1%.
4-tert-butylcyclohexanol is a potent TRPV1 antagonist and is an effective active ingredient suitable for sensitive skin. The addition of the 4-tert-butyl cyclohexanol can adjust the tolerance threshold of skin, and simultaneously, the 4-tert-butyl cyclohexanol can be used as a sensitive regulator to reduce the calcium ion flow in cell membranes and restore the skin to a normal and healthy state.
In a preferred embodiment of the present invention, the amount of the extract of the plant of the genus Pteridium is 0.01 to 0.05% by mass, for example, 0.01%, 0.02%, 0.03%, 0.04%, or 0.05%.
The skin barrier function is mainly located in the stratum corneum. The brick wall model is the currently accepted model of the epidermal stratum corneum barrier structure. It consists mainly of keratinocytes and their cornified envelopes (brick) and intercellular lipid bilayers (mud). Paphiopediin, endocrinin, filaggrin, etc. are cross-linked to form cornification capsule, and horny cells are embedded in the cornification capsule to form the physical barrier structure of the skin. FLG is a hydrophilic protein in the epidermal stratum corneum, mainly present in the stratum granulosum. When keratinocytes differentiate from the stratum granulosum to the stratum corneum, the mitogen of the stratum granulosum is rapidly dephosphorylated to soluble FLG. Monomeric FLG binds to keratin filaments, making them denser, while as keratinocytes mature and dehydrate, FLG decomposes to produce a large amount of natural moisturizing factors, which are critical to maintaining skin hydration and skin barrier. LOR and INV are 2 important terminally differentiated proteins, both of which are involved in the formation of the cornified envelope and play an important role in maintaining the skin barrier function. LEKTI is a novel serine protease inhibitor, which can inhibit the degradation of keratinocyte desmoplakin by serine protease, and improve the intercellular adhesion of stratum corneum, thereby protecting the skin barrier.
Researches show that the pteris plant extract can improve the expression of FLG, LOR, INV and LEKTI, thereby improving the stability of the brick wall structure of the epidermis barrier, enhancing the binding force of the brick wall and further improving the skin barrier function.
In a preferred embodiment of the present invention, the patchouli leaf extract is 0.1 to 1% by mass, for example, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9% or 1%.
The patchouli leaf extract can effectively relieve the burning sensation and the stabbing pain sensation of the skin caused by skin irritation, accelerate the barrier function repair of the damaged skin, reduce the water loss rate of the skin and simultaneously visually relieve the erythema effect of the skin.
In a preferred embodiment of the present invention, the centella asiatica leaf extract is 0.01 to 0.05% by mass, for example, 0.01%, 0.02%, 0.03%, 0.04%, or 0.05%.
The centella asiatica extract can reduce the production of proinflammatory mediators (IL-1, MMP-1), improve and repair the barrier function of the skin, thereby preventing and correcting the immune dysfunction of the skin. Centella asiatica also has antibacterial and antiviral effects, and has antibacterial effects on staphylococcus aureus and proteus; centella asiatica extract also has anti-inflammatory activity.
In a preferred embodiment of the present invention, the content of the scutellaria root extract is 0.01 to 0.8% by mass, for example, 0.01%, 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.5%, 0.6%, 0.7% or 0.8%.
The scutellaria root extract has better anti-inflammatory and antioxidant activity, and can play a role in resisting inflammation by reducing the expression of iNOS and COX-2 proteins and inhibiting the release of inflammatory factors such as NO, TNF-alpha, IL-6 and the like generated by macrophages, and play a role in resisting oxidation by removing excessive DPPH free radicals and superoxide anions.
A method for preparing a soothing and anti-allergy composition, comprising the steps of:
mixing ceramide 3, herba Cisii Eriophoroidei plant extract, folium Agastaches extract, 4-tert-butylcyclohexanol, folium Centellae extract, scutellariae radix extract, and deionized water at a certain proportion, and stirring to obtain the composition with effects of relieving and resisting allergy.
The application of a soothing and anti-allergy composition in a skin care product is to prepare the skin care product, wherein the skin care product comprises the soothing and anti-allergy composition and a conventional base material; according to the weight percentage, the soothing and anti-allergy composition accounts for 0.1-10% of the total weight of the skin care product, and the conventional base material accounts for 90-99.9% of the total weight of the skin care product;
such conventional bases include, but are not limited to, surfactants, thickeners, conditioning agents, humectants, preservatives, chelating agents, fragrances, deionized water.
The skin care product can be made into various dosage forms of toner, smoothing toner, firming toner, nourishing lotion, nourishing cream, massage cream, essence, eye cream, cleaning foam, cleaning lotion, facial mask, body lotion, body oil and body lotion.
The invention has the beneficial effects that:
1. the invention selects proper raw materials from hundreds of raw materials, and the scientific mixture ratio of various raw materials and hundreds of experiments for efficacy verification prove that after the composition is compounded by the ceramide 3, 4-tert-butylcyclohexanol, the Cirsium plant extract, the patchouli leaf extract, the centella asiatica leaf extract and the scutellaria baicalensis root extract, the effects of relieving, resisting inflammation and repairing barriers can be achieved.
2. The relieving and anti-allergy composition provided by the invention can be used for eliminating symptoms such as burning heat, itching, stabbing pain and tightness caused by inflammatory injury in time after being used for a short time, reducing the nerve sensitivity and playing a role in calming and relieving; the long-term use is beneficial to the repair of the skin barrier, and the instant comfort and long-term repair performance are considered.
3. The preparation method and the application process of the composition provided by the invention are simple and easy for industrial production.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
A soothing and anti-allergy composition comprises the following raw materials in percentage by mass:
example 2
A soothing and anti-allergy composition comprises the following raw materials in percentage by mass:
example 3
A soothing and anti-allergy composition comprises the following raw materials in percentage by mass:
the soothing anti-allergy compositions of examples 1-3 were prepared according to the following preparation method:
mixing ceramide 3, extract of plant of genus Alariaceae, extract of folium Agastaches, 4-tert-butylcyclohexanol, extract of folium Centellae, extract of radix Scutellariae, and deionized water at a certain proportion, and stirring to obtain the composition.
Example 4
The skin lotion containing the soothing and anti-allergy composition comprises the following raw materials in percentage by mass:
soothing anti-allergy composition of example 15%
0.1 percent of phenoxyethanol
Balance of deionized water
The preparation method of the skin lotion containing the soothing and anti-allergy composition comprises the following steps:
adding all the components into deionized water, stirring and mixing, and discharging.
Example 5
The skin moisturizer containing the soothing and anti-allergy composition comprises the following raw materials in percentage by mass:
the soothing anti-allergy composition of example 2 8%
0.1 percent of phenoxyethanol
Balance of deionized water
The preparation method of the skin lotion containing the soothing and anti-allergy composition comprises the following steps:
adding all the components into deionized water, stirring and mixing, and discharging.
Example 6
The skin moisturizer containing the soothing and anti-allergy composition comprises the following raw materials in percentage by mass:
soothing anti-sensitivity composition of example 3%
0.1 percent of phenoxyethanol
Balance of deionized water
The preparation method of the skin lotion containing the soothing and anti-allergy composition comprises the following steps:
adding all the components into deionized water, stirring and mixing, and discharging.
Comparative example 1
A soothing and anti-allergy composition comprises the following raw materials in percentage by mass:
comparative example 2
A soothing and anti-allergy composition comprises the following raw materials in percentage by mass:
comparative example 3
A soothing and anti-allergy composition comprises the following raw materials in percentage by mass:
comparative example 4
A soothing and anti-allergy composition comprises the following raw materials in percentage by mass:
comparative example 5
A soothing and anti-allergy composition comprises the following raw materials in percentage by mass:
comparative example 6
A soothing and anti-allergy composition comprises the following raw materials in percentage by mass:
comparative example 7
A soothing and anti-allergy composition comprises the following raw materials in percentage by mass:
comparative example 8
A soothing and anti-allergy composition comprises the following raw materials in percentage by mass:
comparative example 9
A soothing and anti-allergy composition comprises the following raw materials in percentage by mass:
comparative example 10
A soothing and anti-allergy composition comprises the following raw materials in percentage by mass:
comparative example 11
A soothing and anti-allergy composition comprises the following raw materials in percentage by mass:
comparative example 12
A soothing and anti-allergy composition comprises the following raw materials in percentage by mass:
ceramide 3.4%
Centella asiatica leaf extract 0.05%
The balance of deionized water.
Comparative example 13
A soothing and anti-allergy composition comprises the following raw materials in percentage by mass:
aleurites extract 0.05%
0.8 percent of scutellaria root extract
The balance of deionized water.
Comparative example 14
A soothing and anti-allergy composition comprises the following raw materials in percentage by mass:
aleurites extract 0.05%
The balance of deionized water.
Comparative example 15
A soothing and anti-allergy composition comprises the following raw materials in percentage by mass:
patchouli leaf extract 0.9%
The balance of deionized water.
Comparative examples 1 to 15 were prepared as follows:
adding all the raw material components into a container, stirring and mixing, and discharging.
The following tests were carried out for examples 1 to 3 and comparative examples 1 to 15:
test example 1 Hyaluronidase inhibition test
Hyaluronic Acid (HA) plays a major role in maintaining skin moisture and elasticity, wound healing and angiogenesis, etc., and at the same time, it is also involved in vasodilation and allergic reactions, and thus HAs a great relationship with skin sensitivity. Hyaluronidase is an HA-specific lyase, whose overactivity leads to degradation of HA, leading to an inflammatory response of the skin. The hyaluronidase inhibition experiment is the most typical in vitro method for evaluating the anti-allergic activity, the anti-allergic activity of a substance is evaluated by taking the hyaluronidase inhibition rate as an index, and the higher the hyaluronidase inhibition rate is, the stronger the anti-allergic activity is.
Measuring by adopting an Elson-Morgan method, taking 0.1ml of 0.25mmol/L CaCl2 solution and 0.5mL hyaluronidase solution, preserving the temperature at 37 ℃ for 20min, respectively adding 0.5mL of the relieving and anti-allergy composition prepared in the examples 1-3 and the comparative examples 1-15, and continuing preserving the temperature at 37 ℃ for 20min; adding 0.5mL sodium hyaluronate solution, keeping the temperature at 37 ℃ for 30min, and standing at normal temperature for 5min; adding 0.1mL0.4mol/L NaOH solution and 0.5mL acetylacetone solution, heating in a boiling water bath for 15min, and immediately cooling for 5min with ice water; adding 1.0mL of Ellisib reagent, diluting with 3.0mL of anhydrous ethanol, standing for 20min for color development, and measuring the absorbance value with a spectrophotometer.
In the formula: a is the ABS value of the control solution (the sample solution is replaced by acetic acid buffer solution); b is the ABS value of a control blank solution (acetic acid buffer solution is used for replacing the sample solution and the enzyme solution); c is ABS value of the soothing and anti-allergy composition; d is the ABS value of the blank sample solution (the enzyme solution is replaced by acetic acid buffer solution).
In the experiment, the A group samples are firstly subjected to wavelength scanning in the range of 450-700nm to determine the maximum absorption wavelength, and then the ABS value measurement is respectively carried out at the maximum absorption wavelength by taking deionized water as a reference, and the results are shown in Table 1:
TABLE 1
Test example 2 evaluation of erythrocyte hemolytic Properties
The erythrocyte hemolysis experiment is one of the alternatives of the rabbit eye irritation experiment (Draizetest), and the basic principle is to evaluate the damage of chemicals to eye tissue cells by measuring the dissolving amount and the denaturation degree of hemoglobin. The RBC test is used internationally for eye irritation studies for evaluation of chemicals such as cosmetics and raw materials.
A soothing and anti-allergy composition prepared in examples 1-3 and comparative examples 1-15 was subjected to a red blood cell hemolysis test according to the RBC test method and grading standards of the European Alternatives validation center (ECVAM). Wherein HD50 is the sample concentration when 50% erythrocyte is hemolyzed, DI is the protein denaturation index, L/D is the ratio of HD50 to DI, and the specific judgment standard is shown in Table 2:
TABLE 2
The results of the judgment of the irritability of each sample to be tested are shown in table 3:
TABLE 3
The soothing and anti-allergy composition prepared in the comparative examples 1-15 is respectively prepared into skin lotion containing the soothing and anti-allergy composition, and the skin lotion comprises the following raw materials in percentage by mass:
a soothing and anti-allergy composition 9%
0.1 percent of phenoxyethanol
Balance of deionized water
The preparation method of the skin lotion containing the soothing and anti-allergy composition comprises the following steps:
adding all the components into deionized water, stirring and mixing, and discharging.
The skin lotions prepared in examples 4 to 6 and comparative examples 1 to 15 were subjected to the following tests:
test example 3 skin barrier function test
Testing the main body: a total of 90 volunteers. Of these, 9 males and 81 females were aged 18-37 years, with the mean age (29.6 ± 5.4) being randomized into 18 groups of 5 individuals each. Exclusion criteria: (1) those allergic to this type of product (query for medical history); (2) severe infection at the skin lesion, other severe complications and general infection; (3) a woman who is nursing or preparing for pregnancy; (4) those with unclear consciousness or those with mental disease and those who cannot express them clearly; (5) patients with blood coagulation insufficiency, such as hemophilia and thrombocytopenia.
The test method comprises the following steps: the moisture content of the stratum corneum and the amount of percutaneous water loss (TEWL) were measured using the German CK company multi-probe skin test system MPA9, CM825 (moisture test probe) and TM300 (moisture loss test probe). The skin care water containing the soothing and anti-allergy composition provided by the examples 4-6 and the skin care water containing the soothing and anti-allergy composition prepared by the comparative examples 1-15 are respectively used for cleaning the skin to be tested before the test, and are quietly tested after entering the test environment for 30min, the non-skin damage parts of the cheeks are respectively detected, and the test results are shown in the table 4 after statistics.
TABLE 4
As can be seen from Table 1, the composition provided by the invention has good hyaluronidase inhibition rate, and the hyaluronidase inhibition rate is lower in the single-component comparative examples 14-15, the two-component comparative examples 12-13, the three-component comparative examples 10-11, the four-component comparative examples 7-9 and the five-component comparative examples 1-6, but the hyaluronidase inhibition rate is increased, but the difference still exists with the composition provided by the invention, and the hyaluronidase inhibition rate is gradually increased, which shows that the soothing and anti-allergy composition provided by the invention has good anti-allergy and soothing characteristics.
As can be seen from Table 3, the soothing and anti-allergy composition provided by the invention has no irritation and is suitable for various skin types.
From table 4, the soothing and anti-allergy composition provided by the invention has good water retention capability after being compounded with the components, and is beneficial to repairing the skin barrier function.
In the description of the specification, reference to the description of "one embodiment," "an example," "a specific example" or the like means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
The foregoing is illustrative and explanatory only and is not intended to be exhaustive or to limit the invention to the precise embodiments described, and various modifications, additions, and substitutions may be made by those skilled in the art without departing from the scope of the invention or exceeding the scope of the claims.
Claims (10)
1. A soothing and anti-allergy composition is characterized by comprising the following raw materials in percentage by mass:
2. a soothing and anti-allergy composition according to claim 1, wherein the ceramide 3 is present in an amount of 0.1-0.5% by weight.
3. A soothing and anti-allergy composition according to claim 1, characterized in that the 4-tert-butylcyclohexanol is in a mass percentage of 0.4-1%.
4. A soothing and anti-allergy composition according to claim 1, wherein the mass percentage of the extract of the plant of the genus Pteridium is 0.01-0.05%.
5. A soothing and anti-allergy composition according to claim 1, characterized in that the patchouli leaf extract is 0.1-1% by mass.
6. A soothing and anti-allergy composition according to claim 1, wherein the centella asiatica leaf extract is present in an amount of 0.01 to 0.05% by weight.
7. The soothing and anti-allergy composition according to claim 1, wherein the scutellaria baicalensis root extract is 0.01-0.8% by weight.
8. A process for the preparation of a soothing and anti-allergy composition according to any of claims 1 to 7, comprising the steps of:
mixing ceramide 3, herba Cisii Eriophoroidei plant extract, folium Agastaches extract, 4-tert-butylcyclohexanol, folium Centellae extract, scutellariae radix extract, and deionized water at a certain proportion, and stirring to obtain the composition with effects of relieving and resisting allergy.
9. Use of a soothing and anti-sensitivity composition according to any of claims 1 to 7, for the preparation of a skin care product comprising the soothing and anti-sensitivity composition and a conventional base; according to the weight percentage, the soothing and anti-allergy composition accounts for 0.1-10% of the total weight of the skin care product, and the conventional base material accounts for 90-99.9% of the total weight of the skin care product;
such conventional bases include, but are not limited to, surfactants, thickeners, conditioning agents, humectants, preservatives, chelating agents, fragrances, deionized water.
10. The use of a soothing and anti-allergy composition according to claim 9, wherein the skin care product is in the form of a toner, a smoothing toner, a firming toner, a nourishing lotion, a nourishing cream, a massage cream, a essence, an eye cream, a cleansing foam, a cleansing water, a facial mask, a body lotion, a body oil, a body lotion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211604730.3A CN115919710A (en) | 2022-12-13 | 2022-12-13 | Soothing and anti-allergy composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211604730.3A CN115919710A (en) | 2022-12-13 | 2022-12-13 | Soothing and anti-allergy composition and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115919710A true CN115919710A (en) | 2023-04-07 |
Family
ID=86550155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211604730.3A Pending CN115919710A (en) | 2022-12-13 | 2022-12-13 | Soothing and anti-allergy composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115919710A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109528595A (en) * | 2018-12-29 | 2019-03-29 | 广州睿森生物科技有限公司 | A kind of plant composition for skin care and preparation method thereof |
| CN112569151A (en) * | 2020-11-12 | 2021-03-30 | 名臣健康用品股份有限公司 | Anti-allergy repairing barrier composition and preparation method and application thereof |
| CN113332222A (en) * | 2021-07-23 | 2021-09-03 | 衢州市衢江区廿里镇养和残疾人之家 | Whitening anti-inflammatory moisturizing mask and preparation method thereof |
| CN114344219A (en) * | 2022-01-27 | 2022-04-15 | 山西万龄国际贸易有限公司 | Aromatic plant composition for treating red swelling, itching and pain of skin and preparation method thereof |
-
2022
- 2022-12-13 CN CN202211604730.3A patent/CN115919710A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109528595A (en) * | 2018-12-29 | 2019-03-29 | 广州睿森生物科技有限公司 | A kind of plant composition for skin care and preparation method thereof |
| CN112569151A (en) * | 2020-11-12 | 2021-03-30 | 名臣健康用品股份有限公司 | Anti-allergy repairing barrier composition and preparation method and application thereof |
| CN113332222A (en) * | 2021-07-23 | 2021-09-03 | 衢州市衢江区廿里镇养和残疾人之家 | Whitening anti-inflammatory moisturizing mask and preparation method thereof |
| CN114344219A (en) * | 2022-01-27 | 2022-04-15 | 山西万龄国际贸易有限公司 | Aromatic plant composition for treating red swelling, itching and pain of skin and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110200830B (en) | Anti-inflammatory and allergy-relieving repair composition and preparation method and application thereof | |
| US8101214B2 (en) | Composition for skin external application containing complex of herbal extracts | |
| CN103127269A (en) | Extractive of Chinese herbal compound and cosmetics including active ingredients | |
| KR102501046B1 (en) | Cosmetic composition for moisturizing and improvement of skin itching comprising the extract of natural products | |
| CN111228196A (en) | Composition based on wheat germ extracting solution, soothing infant cream and preparation method thereof | |
| CN105560155A (en) | Cosmetic composition containing goat milk and application thereof | |
| CN113925824A (en) | Soothing and repairing composition and preparation method thereof | |
| CN114886813B (en) | Anti-aging plant extract composition and preparation method and application thereof | |
| CN111419773A (en) | Plant extract composition for skin anti-aging repair, application and essence containing composition | |
| CN112137921A (en) | Soothing and anti-allergy composition, application thereof and soothing and anti-allergy mask | |
| CN113456568A (en) | Composition for soothing, repairing and moisturizing skin and preparation method and application thereof | |
| KR101481177B1 (en) | Cosmetic composition containing soothing complex | |
| KR20050110720A (en) | Cosmetic composition for moisturizing effect on the skin | |
| CN116617106A (en) | Protopanaxatriol saponin allergy-relieving repairing composition, and preparation method and application thereof | |
| CN111991309A (en) | Composition with repairing and moisturizing effects and preparation method and application thereof | |
| CN109431842B (en) | Eczema cream for children | |
| CN115919710A (en) | Soothing and anti-allergy composition and preparation method and application thereof | |
| CN115177570A (en) | Composition with soothing and repairing effects and preparation method and application thereof | |
| KR100964428B1 (en) | Cosmetic composition containing natural medicinal plant extract for alleviating skin inflammation | |
| KR102071600B1 (en) | Cream composition manufacturing method for preventing of sensitive-skin and skin-trouble | |
| CN111939097A (en) | Moisturizing and allergy-relieving composition and application thereof | |
| CN113499271A (en) | Anti-allergy compound and preparation method and application thereof | |
| CN113201421A (en) | Graphene bacteriostatic skin-moistening perfumed soap and preparation method thereof | |
| CN111096914A (en) | Hemp leaf mask for cleaning and balancing face and preparation method thereof | |
| CN112972323A (en) | Hemp leaf essence and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230407 |